Table 1. Characteristics of patients diagnosed with RRMS during the period [1982–2011] in Western-Normandy.

Factors	Number of RRMS patients (%)	Number of second-line DMT initiation (n)	Median delay(a) [CI 95%]	p-value(b)
Gender	733	199		0.069
Males	186 (25.4%)	60	5.34 [3.91–8.08]
Females	547 (74.6%)	139	8.83 [6.58–9.58]
Age at disease onset	733	199		0.1881
[6–25 years]	205 (28%)	73	6.41 [4.5–9.58]
[26–35 years]	280 (38.2%)	75	9.08 [6.83–12.75]
[36–45 years]	177 (24.1%)	39	5.75 [4.59–9.58]
>45 years	71 (9.7%)	12	5.33 [3.91-.]
Periods of diagnosis	733	199		<0.001
[1982–2000]	204 (27.8%)	55	13.75 [10.33–14.25]
[2001–2011]	529 (72.2%)	144	4.83 [3.83–5.66]
County of residence at diagnosis	733	199		0.0015
Manche	247 (33.7%)	76	5.58 [3.92–8]
Calvados	378 (51.6%)	97	9.08 [6.83–10.33]
Orne	108 (14.7%)	26	9.5 [5.33–15.83]
EDI (quintiles)	725	198		0.1923
Q1	108 (14.7%)	35	5.83 [4.83–7.75]
Q2	115 (15.7%)	28	9.08 [8.34–13]
Q3	155 (21.1%)	41	9 [5.33–14.25]
Q4	183 (25%)	55	6.58 [5–12.25]
Q5	164 (22.4%)	39	9.5 [6.58–15.83]

(a) Kaplan Meier survival analysis estimates median delay to access a second-line DMT.

(b) Log rank test used for calculation of significance.

DMT: Disease Modifying Treatment. RRMS: Relapsing Remitting Multiple Sclerosis. CI: Confidence Interval. EDI: European Deprivation Index.